Brain 17 Vienna

Targeted therapy

• Bevacizumab

=> probably no need to cross the BBB

• EGFR inhibitors (erlotinib, gefitinib…) => only in patients with sensitizing EGFR mutation

• ALK inhibitors (crizotinib, ceritinib…)

=> only in patients with EML4-ALK translocation